Publication | Closed Access
P1.13-44 Safety, PK, and Preliminary Antitumor Activity of the Oral EGFR/HER2 Exon 20 Inhibitor TAK-788 in NSCLC
26
Citations
0
References
2018
Year
Inhibitor Tak-788MedicinePharmacologyP1.13-44 SafetyPharmacotherapyAnti-cancer AgentCancer TreatmentOncologyRadiation OncologyPreliminary Antitumor Activity
No additional data available for this publication yet. Check back later!